A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer

Tas, Faruk; Guney, Pınar; Derin, Duygu; Aydiner, Adnan; Topuz, Erkan

doi:10.1007/s10147-007-0740-4

A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer

Atıf İçin Kopyala

Tas F., Guney N., Derin D., Aydiner A., Topuz E.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.13, sa.2, ss.156-160, 2008 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 13 Sayı: 2
Basım Tarihi: 2008
Doi Numarası: 10.1007/s10147-007-0740-4
Dergi Adı: INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.156-160
İstanbul Üniversitesi Adresli: Evet

Özet

Background. Both gemcitabine and pegylated liposomal doxorubicin (PLD) are antineoplastic drugs with clinical activity in patients with platinum-resistant ovarian cancer. The present study was designed to assess the efficacy and safety of biweekly scheduled gemcitabine and PLD combination therapy in such patients.